Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Position Boosted by Rhumbline Advisers

Rhumbline Advisers increased its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 9.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 119,285 shares of the company’s stock after buying an additional 10,291 shares during the quarter. Rhumbline Advisers’ holdings in Syndax Pharmaceuticals were worth $2,449,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. grew its holdings in Syndax Pharmaceuticals by 13.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 577,022 shares of the company’s stock worth $12,469,000 after buying an additional 70,555 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in Syndax Pharmaceuticals by 54.3% in the second quarter. Assenagon Asset Management S.A. now owns 428,949 shares of the company’s stock worth $8,806,000 after purchasing an additional 151,021 shares during the period. Trexquant Investment LP acquired a new stake in Syndax Pharmaceuticals in the fourth quarter worth approximately $3,101,000. Vanguard Group Inc. lifted its position in Syndax Pharmaceuticals by 19.9% in the fourth quarter. Vanguard Group Inc. now owns 4,335,353 shares of the company’s stock worth $93,687,000 after purchasing an additional 718,051 shares during the period. Finally, Point72 Asset Management L.P. lifted its position in Syndax Pharmaceuticals by 35.3% in the fourth quarter. Point72 Asset Management L.P. now owns 2,834,499 shares of the company’s stock worth $61,254,000 after purchasing an additional 740,298 shares during the period.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Barclays upped their target price on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the stock an “overweight” rating in a research report on Thursday, August 15th. Scotiabank downgraded Syndax Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, June 14th. Citigroup upped their target price on Syndax Pharmaceuticals from $30.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Stifel Nicolaus upped their target price on Syndax Pharmaceuticals from $40.00 to $42.00 and gave the stock a “buy” rating in a research report on Wednesday, June 26th. Finally, Jefferies Financial Group assumed coverage on Syndax Pharmaceuticals in a research report on Friday, June 28th. They issued a “buy” rating and a $37.00 target price for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, Syndax Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.33.

Syndax Pharmaceuticals Stock Performance

Shares of NASDAQ:SNDX opened at $18.00 on Thursday. Syndax Pharmaceuticals, Inc. has a one year low of $11.22 and a one year high of $25.34. The stock has a fifty day moving average of $20.91 and a 200-day moving average of $21.23. The company has a market capitalization of $1.53 billion, a PE ratio of -5.59 and a beta of 0.91.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its earnings results on Thursday, August 1st. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.11. The business had revenue of $3.50 million during the quarter. The firm’s quarterly revenue was up 3499999990.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.64) EPS. As a group, research analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.66 EPS for the current fiscal year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).